25 related articles for article (PubMed ID: 22993299)
1. Association of single nucleotide variants in
Assis-Mendonça GR; Campos LG; Delamain MT; de Brito ABC; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Lima CSP
Leuk Lymphoma; 2023 Dec; 64(13):2165-2177. PubMed ID: 37647140
[TBL] [Abstract][Full Text] [Related]
2. Association of angiogenesis and inflammation-related gene functional polymorphisms with early-stage breast cancer prognosis.
Korobeinikova E; Ugenskiene R; Insodaite R; Rudzianskas V; Jaselske E; Poskiene L; Juozaityte E
Oncol Lett; 2020 Jun; 19(6):3687-3700. PubMed ID: 32391092
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell RNA-Seq Reveals the Promoting Role of Ferroptosis Tendency During Lung Adenocarcinoma EMT Progression.
Yao J; Zhang Y; Li M; Sun Z; Liu T; Zhao M; Li Z
Front Cell Dev Biol; 2021; 9():822315. PubMed ID: 35127731
[TBL] [Abstract][Full Text] [Related]
4. Association of VEGF haplotypes with breast cancer risk in North-West Indians.
Sambyal V; Guleria K; Kapahi R; Manjari M; Sudan M; Uppal MS; Singh NR
BMC Med Genomics; 2021 Aug; 14(1):209. PubMed ID: 34429108
[TBL] [Abstract][Full Text] [Related]
5. Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.
Vieira-Monteiro Hde A; Freitas-Alves DR; Sobral-Leite M; Delou JM; Goulart-Citrangulo SM; do Nascimento CT; E Castro TN; Koifman S; Perini JA; Vianna-Jorge R
Cancer Biol Ther; 2016 Jun; 17(6):674-83. PubMed ID: 27195611
[TBL] [Abstract][Full Text] [Related]
6. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.
Ochnik AM; Peterson MS; Avdulov SV; Oh AS; Bitterman PB; Yee D
Neoplasia; 2016 Feb; 18(2):100-10. PubMed ID: 26936396
[TBL] [Abstract][Full Text] [Related]
7. CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.
Flister MJ; Endres BT; Rudemiller N; Sarkis AB; Santarriaga S; Roy I; Lemke A; Geurts AM; Moreno C; Ran S; Tsaih SW; De Pons J; Carlson DF; Tan W; Fahrenkrug SC; Lazarova Z; Lazar J; North PE; LaViolette PS; Dwinell MB; Shull JD; Jacob HJ
Cancer Res; 2014 Nov; 74(22):6419-29. PubMed ID: 25172839
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor gene polymorphism (-634G/C) and breast cancer risk.
Yao W; Yan R; Ma L; Wan H; Yu Y; Cheng X; Li Y
Tumour Biol; 2014 Aug; 35(8):7793-8. PubMed ID: 24816918
[TBL] [Abstract][Full Text] [Related]
9. No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women.
Dorjgochoo T; Zheng Y; Gao YT; Ma X; Long J; Bao P; Zhang B; Wen W; Lu W; Zheng W; Shu XO; Beeghly-Fadiel A
Cancer Epidemiol; 2013 Oct; 37(5):619-24. PubMed ID: 23850146
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
Jin Q; Hemminki K; Enquist K; Lenner P; Grzybowska E; Klaes R; Henriksson R; Chen B; Pamula J; Pekala W; Zientek H; Rogozinska-Szczepka J; Utracka-Hutka B; Hallmans G; Försti A
Clin Cancer Res; 2005 May; 11(10):3647-53. PubMed ID: 15897560
[TBL] [Abstract][Full Text] [Related]
11. The role of vascular endothelial growth factor a polymorphisms in breast cancer.
Sa-Nguanraksa D; O-Charoenrat P
Int J Mol Sci; 2012 Nov; 13(11):14845-64. PubMed ID: 23203097
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
Maae E; Andersen RF; Steffensen KD; Jakobsen EH; Brandslund I; Sørensen FB; Jakobsen A
Anticancer Res; 2012 Sep; 32(9):3619-27. PubMed ID: 22993299
[TBL] [Abstract][Full Text] [Related]
13. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
14. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
